Product Information
ARIPIPRAZOLE ODT 15 MG TABLET is a generic product labeled by Viona Pharmaceuticals Inc., priced at $2.2239 per EA under NDC 72578010706. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Aug 28, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Aripiprazole market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
15 mg/1
Manufacturer
Viona Pharmaceuticals Inc.NDC
72578010706
Classification
Generic
Dosage Form
TABLET, ORALLY DISINTEGRATING
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ARIPIPRAZOLEApproval Type
Generic (ANDA)
FDA Application
ANDA090165FDA Approved
8/28/2018
TE Code
AB
On Market Since
7/20/2022
Pharmacological Classes
Price Statistics
The NADAC for ARIPIPRAZOLE ODT 15 MG TABLET has been published 129 times since Apr 17, 2024, and over the history we have for it it has declined 84.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.2239 per EA |
|---|---|
| All-time high | $14.2441 (May 15, 2024) |
| All-time low | $2.2239 (Sep 23, 2026) |
| 52-week high | $4.5277 |
| 52-week low | $2.2239 |
| Median price | $4.1372 |
| Average price | $5.0286 |
| Largest weekly change | -36.5% (Jul 17, 2024) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
The matcher finds 17 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 94% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Viona Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Aripiprazole market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ARIPIPRAZOLE ODT 15 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ARIPIPRAZOLE ODT 15 MG TABLET, manufactured by Viona Pharmaceuticals Inc., is $2.2239 per EA (NDC 72578010706), effective Sep 30, 2026.
How has the price of ARIPIPRAZOLE ODT 15 MG TABLET changed over time?
Over the history we have for it, the NADAC for ARIPIPRAZOLE ODT 15 MG TABLET has declined 84.4%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for ARIPIPRAZOLE ODT 15 MG TABLET?
Since Apr 17, 2024, the NADAC for ARIPIPRAZOLE ODT 15 MG TABLET has ranged from a low of $2.2239 (Sep 23, 2026) to a high of $14.2441 (May 15, 2024), with a median of $4.1372 per EA.
Are there cheaper alternatives to ARIPIPRAZOLE ODT 15 MG TABLET?
Yes. 17 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ARIPIPRAZOLE 15 MG TABLET, is $0.1312 per EA — about 94% below ARIPIPRAZOLE ODT 15 MG TABLET.
Who manufactures ARIPIPRAZOLE ODT 15 MG TABLET?
ARIPIPRAZOLE ODT 15 MG TABLET (NDC 72578010706) is labeled by Viona Pharmaceuticals Inc., and CMS classifies it as a generic product.